title: Breast-conserving therapy (BCT) for early-stage breast cancer.
abstract: Several patient and tumor factors go into the decision process to determine whether a breast cancer patient is a good candidate for breast-conserving therapy. The patient must be seen by all disciplines before any therapeutic intervention. When used appropriately, breast-conserving therapy produces maximal disease control and improves quality of life in patients with early-stage breast cancer.
authors.affiliation: Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida 32610-0385, USA. bendark@shands.ufl.edu
authors.forename: Rashmi K
authors.initials: RK
authors.lastname: Benda
authors.forename: Nancy Price
authors.initials: NP
authors.lastname: Mendenhall
authors.forename: D Scott
authors.initials: DS
authors.lastname: Lind
authors.forename: Juan C
authors.initials: JC
authors.lastname: Cendan
authors.forename: Barbara F
authors.initials: BF
authors.lastname: Shea
authors.forename: Lisa C
authors.initials: LC
authors.lastname: Richardson
authors.forename: Edward M
authors.initials: EM
authors.lastname: Copeland
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000528:radiation effects; D015412:Mastectomy, Segmental; D009367:Neoplasm Staging; D018579:Patient Selection; D011379:Prognosis; D011788:Quality of Life; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal